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The objective of the study was to evaluate the efﬁcacy of a meloxicam oral suspension
(MOS) for pain and inﬂammation control after castration in horses. The study consisted of
88 healthy, unbroken, 2-year-old mixed breed horses (primarily Quarter horse and draft
type). Group 1 animals (n ¼ 44) received MOS at the dose of 0.6 mg per kg body weight
administered orally at the time of castration then daily for two consecutive days. Group 2
animals (n ¼ 44) received 0.9% saline at the dose of 1 mL per 25-kg body weight
administered orally at the time of castration then daily for two consecutive days. Animals
were castrated on day 0 and observed for clinical signs of pain and inﬂammation for four
(4) consecutive days. Pain behavior scores and visual analog scores were signiﬁcantly
greater in control animals over meloxicam-treated animals at all observation periods (P <
.05). The Stiffness Score at the time of leaving the chute was signiﬁcantly different in
control animals over meloxicam-treated animals at all observation periods (P < .05). The
meloxicam-treated animals had signiﬁcantly greater movement indices 24 to 96 hours
after castration (P < .05). Meloxicam-treated animals had signiﬁcantly lower swelling than
control animals at all observation periods (day 1, day 2, and day 3; P < .05). It is concluded
that daily administration of MOS at a dose of 0.6 mg/kg for 3 days signiﬁcantly reduces
postsurgical pain and inﬂammation in horses for at least 4 days after castration.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Castration is the most common surgical procedure per-
formed on horses [1–4]. Although it is considered a routine
elective procedure, castration is a major, invasive surgery
with the potential for considerable postsurgical complica-
tions and postoperative pain. The Canadian Veterinarya Veterinary Labora-
6J7.
).
ier Inc. This is an open accMedical Association and American Veterinary Medical As-
sociation recommend the use of perioperative analgesics for
castration of all horses, mules, and donkeys [5,6].
Currently, veterinarians use nonsteroidal anti-
inﬂammatory agents (NSAIDs) and narcotics for
postsurgical control of pain [5–9]; however, there are few
published studies evaluating the efﬁcacy of anti-
inﬂammatory and analgesic agents after castration in
horses [10–13]. Meloxicam has been evaluated as a
method to control pain after castration in horses, but there
was an insufﬁcient number of animals (three in eachess article under the CC BY-NC-ND license (http://creativecommons.org/
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[11]. Because of the wide variation in behavior of indi-
vidual animals, larger sample sizes are needed to show
signiﬁcant differences between treatment groups when
evaluating the effects of pain medications on postsurgical
pain. Although several large studies in food animals
demonstrate the effects of NSAIDs in managing post-
operative pain after castration, to our knowledge, these
studies have not yet been performed in horses for a
postoperative period of longer than 24 hours [10–13].
Recently, a meloxicam oral suspension (MOS) (15 mg/
mL meloxicam) has been developed for postsurgical pain
and inﬂammation in cattle and horses (Alberta Veterinary
Laboratories, Calgary, Alberta, Canada). Currently, MOS is
registered in Canada for the control of pain and inﬂam-
mation in cattle undergoing surgical or band castration.
This article describes the pharmacokinetic and efﬁcacy
studies of MOS for controlling pain and inﬂammation after
surgical castration in horses at daily dosage of 0.6 mg/kg.
2. Materials and Methods
2.1. Pharmacokinetic Study
2.1.1. Study Design
The pharmacokinetic study was not a blinded study. All
horses received meloxicam at a dose of 0.6 mg per kg body
weight orally once daily for ﬁve treatments (times 0, 14, 48,
72, and 96 hours). The meloxicam was administered into
the mouth via a syringe with a long plastic extension to
ensure that all the medication was swallowed. The study
was conducted according to good clinical practice (VICH GL
GL9 [GCP]dGOOD CLINICAL PRACTISE [June 2000]). The
study was reviewed and approved by an Institutional
Ethical Care and Use Committee.
2.1.2. Animals
In the pharmacokinetic study, horses were healthy
Quarter horses (six geldings and six nonpregnant mares)
between 8 and 20 years of age. The meanweight was 542
85.1 kg (range, 220–702 kg). Horses were identiﬁed with a
numbered neck collar.
2.1.3. Blood Sample Collection
Blood samples (approximately 10 mL) were collected in
labeled, heparinized tubes (Green Top) from the jugular
vein of each animal at the following times: 1 hr (pre-
medication), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 24,
26, 48, 50, 72, 74, 96, and 98 hours. Plasma was separated
by centrifugation (2000g) in a temperature-controlled
centrifuge (approximately 5C) for 20 minutes. After sep-
aration, plasma was withdrawn and aliquoted into prela-
beled plastic vials (minimum of three). Samples were
placed in frozen storage (approximately 20C) to wait
processing for analysis.
2.1.4. Plasma Meloxicam Analysis
Samples were subjected to in vitro analysis for quanti-
ﬁcation of meloxicam by a validated procedure using a
high-performance liquid chromatography system (HPLC)
according to a previously reported validated procedure[14]. An Agilent 1200 HPLC (Mississauga, Ontario) equipped
with a quaternary pump, an auto sampler, UV detector, and
Chem Station software was used for all analysis. Peroxicam
was used as an internal standard.
The analytical methods were fully documented and
validated a priori to demonstrate (where applicable)
acceptable linearity over the entire concentration range
(without extrapolation), precision (reproducibility), accu-
racy, speciﬁcity, sensitivity (limit of quantitation), recovery,
and stability of the analyte in the target matrix under
anticipated storage conditions and intervals of the study.
Preparation and storage of in-process analytical samples
accommodated the requirements of the method. Standards
and controls were prepared for and analyzed in each run to
assure that the complete analytical method, sample prep-
aration, extraction, clean-up, and instrumental analysis
perform according to acceptable criteria, as indicated by
precision and accuracy determinations.
Pharmacokinetic analysis was performed using vali-
dated software (PK Solutions, Montrose, CO).2.2. Castration Efﬁcacy Study
2.2.1. Study Design
This was a randomized, controlled, blinded study. The
number of animals in each treatment group was based on
power calculations for each variable evaluated. Eighty-
eight young (2 years), healthy horses were randomly
assigned to two treatment groups. Group 1 horses (n ¼ 44)
received MOS at the dose of 0.6 mg per kg body weight
(1 mL per 25-kg body weight) administered orally at the
time of castration then once daily for two (2) consecutive
days. Group 2 horses (n ¼ 44) received 0.9% saline at the
dose of 1 mL per 25-kg body weight administered at the
time of castration then once daily for two (2) consecutive
days. Individuals scoring animals, caring for the animals,
and performing health assessments and bodyweights were
blinded to the treatment groups. The statistician was un-
blinded at the end of the study. Animals were castrated on
day 0 and observed for clinical signs of pain and inﬂam-
mation for four (4) consecutive days. The study was per-
formed over three consecutive weeks with 28, 30, and 30
horses examined each week, respectively. Horses were
randomly assigned to treatment groups, each week of the
study so that an equal number of animals in each group
were represented each week.
The study was conducted according to good clinical
practice (VICH GL GL9 [GCP]dGOOD CLINICAL PRACTISE
[June 2000]). The study was reviewed and approved by an
Institutional Ethical Care and Use Committee.
2.2.2. Animals
All horses were unbroken, healthy, 2 years of age, and of
mixed breeds (primarily Quarter horse and draft type).
Horses were identiﬁed with a numbered neck collar and
number sprayed on the hip. The MOS-treated animals
weighed 484.9  115.8 kg (mean and standard deviation)
with a minimum and maximum weight of 316 kg and
852 kg, respectively. The saline-treated animals weighed
445.2  77.2 kg (mean and standard deviation) with a
Table 1
Behavioral score for daily evaluation of animals after castration.
Behavior Observation Score
Attitude Bright and alert (responsive to surroundings) 0
Quiet 1
Restless and agitated 2
Depressed and unresponsive 3
Flank
watching
Does not look at ﬂank 0
Looks intermittently at ﬂank
(1–3 times in 5 min)
1
Repeatedly looks at ﬂank or kicks at
abdomen (3–4 times in 5 min)
2
Lies down, rolling, or continual kicking
at abdomen (>5 times 5 min)
3
Head carriage Head (poll) positioned normally above withers 0
Head (poll) held level with withers 1
Head (poll) lowered below withers 2
Weight
shifting
Normal weight distribution on all four limbs 0
Intermittently shifting weight on hind limbs 1
Continually shifting weight on hind limbs 2
Activity At feeder and eating normally 0
Standing or lying quietly with other horses 1
Standing alone away from others 2
Recumbent and uncomfortable 3
Overall Comfortable 0
Mildly painful 1
Moderately painful 2
In severe pain 3
Maximum
score
16
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705 kg, respectively.
2.2.3. Feed, Water, and Housing
All horses were placed on a barley silage ration (58.4%
dry matter) before and during the study. The analysis of
feed on a dry matter basis was 15.1% crude protein (47%
soluble protein and 70% degradable protein), 5.4% lignin,
24.7% acid detergent ﬁber, 34% neutral detergent ﬁber,
3.5% water soluble carbohydrates, 2.6% simple sugars,
24.6% starch, 39% nonﬁbrous carbohydrates, 39.9% fat,
5.2% ash, and 7.32% total digestible nitrogen. The animals
were group housed in a triangular shaped pen (30 meters
 40 meters  40 meters) with 25 meters of bunk space
and two automatic waterers. They had free access to water
and feed throughout the study. They were provided with
straw bedding and a 20% porosity fence for wind and
weather protection. Horses from both treatment groups
were kept in the same pen.
2.2.4. Castration Procedure
As horses were unbroke, they were restrained in a chute
with a hydraulic tilt table. Surgical pain control was ach-
ieved using a combination of sedation and local anesthesia.
Horses were sedated with 0.5 mg/kg xylazine HCl (Xyla-
zine, 100 mg/mL, Rompun, Bayer HealthCare, Mississauga,
Ontario, Canada) IV. Approximately, 20 to 30 mL of lido-
caine hydrochloride with epinephrine (2% lidocaine, Zoetis
Canada, Kirkland, Quebec) was then inﬁltrated in and
around each spermatic cord. Another 10 mL was inﬁltrated
subcutaneously at the base of the scrotum on each side of
the median raphae. A total of 50-mL lidocaine was used in
each horse. The surgical site was cleaned and disinfected
with povidone iodine surgical scrub (Betadine, Wyeth,
Guelph Ontario) followed by an isopropyl alcohol (99%
Isopropyl Alcohol, Alberta Veterinary Laboratories, Calgary,
Alberta) rinse. Horses were castrated using an open
castration technique. Brieﬂy, a 15-cm skin incision was
made over each testicle at the base of the scrotum using a
scalpel. The incision was extended through subcutaneous
tissues and the vaginal tunic to expose the testes and
spermatic cord. The testicle, epididymis, and spermatic
cord were isolated, and an emasculator was placed over
each spermatic cord and clamped for a minimum of 2 mi-
nutes to achieve hemostasis. Skin incisions were stretched
and left open to heal by second intention.
2.2.5. General Health Observations
Animals were observed for general health daily
throughout the study. Animals were continually monitored
for the ﬁrst 6 hours postcastration for adverse events such
as bleeding and colic.
2.2.6. Behavior Score
A Composite Pain Scale (CPS) was used to evaluate
behavioral signs of pain in horses on day 0 (late after-
noon, at least 2 hours after castration), day 1 (early
morning), day 2 (early morning), and day 3 (early
morning). This numerical rating scale is made up of nine
categories of behavior related to pain after castration inhorses with a maximum possible score of 23 points (one
category was not included in the total composite score as
it was only assessed on days 0 and 3; see Table 1). Cat-
egories included evaluation of attitude, ﬂank watching,
head carriage, weight shifting, activity, movement,
swelling, response to palpation, and overall pain. The
scale is based on other scales developed for pain assess-
ment in horses and dogs [15–17] but modiﬁed to reﬂect
speciﬁc behaviors seen in horses after castration [11].
Horses were observed in their home pen and while being
moved through the chute system (during their daily
treatment). Three observers, blinded to treatment groups,
scored all horses to minimize interobserver variance.
Observers were experienced in normal horse behaviors
and were trained on the use of the scoring system before
initiating the trial. Observation began at least 2 to 6 hours
after castration or treatment from the edge of the pen
where the observer would not interfere with the horses’
normal behavior. Horses were not observed during times
when they were lying down and/or asleep or during
feeding time. Each observation period was approximately
2 hours in duration, and each horse was provided a score
after 4 minutes of continual observation. There was no
precastration observation.
2.2.7. Visual Analog Scores
A visual analog score (VAS) was performed by three
blinded observers on days 0, 1, 2, and 3. VAS is a sub-
jective measure of pain where an experienced observer
places a mark on a 100-mm line where one end repre-
sents no pain and the opposite end severe pain. The
distance from the beginning of the line (no pain) to the
observer’s mark is measured in millimeters. Observers
Table 2
Pharmacokinetic parameters after administration of meloxicam oral sus-
pension to horses.
Variable Unit Mean Standard Deviation
Cmax mg/mL 1.70 0.32
Tmax Hr 2.08 0.47
AUCt (mg-hr/mL) 14.08 1.66
AUCN (mg-hr/mL) 17.68 2.09
T1/2 Hr 12.98 3.81
MRT Hr 17.68 2.09
CL(obs area) mL/hr 34.3 4.16
Abbreviations: AUCt, area under blood plasma concentration of melox-
icam versus time curve at time t; AUCN, area under blood plasma con-
centration of meloxicam versus time curve extrapolated to inﬁnity; Cmax,
maximal observed blood plasma meloxicam concentration; CL(obs area),
systemic clearance based on observed data points; MRT, mean residence
time or time for 63.2% of administered meloxicam dose to be eliminated;
Tmax, time at maximum observed plasma meloxicam concentration; T1/2,
time for concentration of plasma meloxicam to diminish by one half.
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during the time the CPS was performed and each
observer scored all horses.
2.2.8. Stiffness Score and Stride Length Measurement
Stride length was measured at days 0 (before castration),
1, 2, and 3 after being castrated. Video images were obtained
as the horse moved past a portion of an alley located at the
end of the squeeze chute. Videowas analyzed by an observer
blinded to treatment. Only horses which passed the video at
a trot were used in the analysis. To obtain stride length in the
horses, measures were taken sequentially as the video was
advanced slowly frame by frame so that an accuratemeasure
between one hind hoof leaving the ground and the next hind
hoof hitting the ground could be obtained. Stride length was
recorded as the distance measured from the toe of one hoof
to the toe of the opposite hoof after calculating the distance
between two reference points in the photograph. The
reference points were the fence posts of the alley which had
a standard measured distance.
A subjective measure of hind limb stiffness was recor-
ded on days 0, 1, 2, and 3 while the horses were being
moved though the chute system. Stiffness was assigned as
0¼ normal (moving normally and freely), 1¼mild stiffness
(slightly stiff in hind legs but still moving freely), 2 ¼
moderate stiffness (obvious hind limb stiffness), 3 ¼ severe
stiffness (reluctant to move), and 4 ¼ very severe stiffness
(unwilling to move).
2.2.9. Accelerometers (Movement Evaluation)
ICE TAG (IceRobotics Ltd, Edinburgh EH30 9 TF, Scot-
land, UK) accelerometers were used to continuously
monitor the movement of animals after castration (day
0 to day 3). Accelerometers were placed on the left hind
limb above the fetlock while the horse was restrained on
the tilt table at the time of castration. It was removed on
day 3 while the wound sites and swelling were evaluated
on the tilt table. The information was downloaded on the
computer. The motion index is a measurement developed
by IceRobotics that provides a broad measurement of the
animal’s activity level. The calculation is performed per
second. For any time period, the index is summed to
provide total activity for the period. Although the move-
ment index was evaluated continuously, information was
recorded each minute of the day. The Movement Index
data were only analyzed when all the horses were in their
home pen (not during treatment, castration, or movement
evaluation).
2.2.10. Inﬂammation and Temperature Measurement (Day 3)
Sheath swelling was measured using callipers on day 3.
Digital callipers were placed horizontally across the pre-
puce at the widest aspect, and the width was measured.
Incision site temperature was also measured using a
surface thermometer (Mastercraft Digital Temperature
Reader, Canadian Tire, Canada). The surface skin tempera-
ture was recorded in the interincisional area.
2.2.11. Sheath Swelling Score
Scrotal swelling of each horse was scored on days 0, 1, 2,
and 3. Scoring was performed chute side during the dailytreatments by an individual blinded to the treatment
groups. A simple descriptive scale was used: 0 ¼ no
swelling, 1 ¼ slight swelling, 2 ¼ moderate swelling, and
3 ¼ severe swelling as a category in the CPS.
2.3. Statistical Analysis
The mean peak (2 hours) and trough (24 hours) plasma
meloxicam concentrations on each day were comparedwith
day 0 means using a t test. Movement index, stride length,
sheath thickness, and skin temperatures were compared
using a t test. Mean CPS pain scores, VAS, stiffness and stride
lengths, ICE TAG motion index, sheath swelling and
inﬂammation measures, and scrotal swelling score were
analyzed using Mann–Whitney test (GraphPad, La Jolla, CA).
The differences between the meloxicam treated and the
control group were considered signiﬁcant when P < .05.
3. Results
3.1. Pharmacokinetics/Pharmacodynamics
The pharmacokinetics data are summarized in Table 2.
The mean plasmameloxicam concentration versus time plot
is provided in Fig. 1. Peak (2 hours posttreatment) and
trough (just before treatments on days 1, 2, 3, and 4) plasma
meloxicam concentrations were also measured (Fig. 1).
There were no differences among the days 0, 1, 2, 3, and 4
peak (2 hours) and trough (24 hours) plasma meloxicam
concentrations (P > .05). Administration of MOS daily over
5 days was not associated with accumulation of the plasma
meloxicam.
3.2. Castration Study
The results of the scores and measurements are sum-
marized in Table 3.
3.2.1. Behavior Score
The median Behavior Score was signiﬁcantly greater in
control animals over meloxicam-treated animals at all
observationperiods (day0:meloxicam¼3.0vs. control¼4.0,
Fig. 1. Plasma meloxicam concentration versus time plots. (Data represent
mean  standard error of all 12 horses.)
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day 2: meloxicam ¼ 2.0 vs. control ¼ 3.0, P ¼ .0048; day 3:
meloxicam ¼ 2.0 vs. control¼ 3.0, P ¼ .0051).
3.2.2. Visual Analog Scores
The Visual Analog Score was signiﬁcantly greater in
control animals over meloxicam-treated animals at all
observation periods (day 0: meloxicam ¼ 18.0 vs. control ¼
28.5, P ¼ .0023; day 1: meloxicam ¼ 10.0 vs. control ¼ 25.5,
P < .0001; day 2: meloxicam ¼ 8.5 vs. control ¼ 17.0, P ¼
.0006; day 3: meloxicam ¼ 9.0 vs. control ¼ 15.0, P ¼
.0040).
3.2.3. Stiffness Score and Stride Length Measurement
Most horses had normal movements at all observation
periods. For this reason, the mean movement scores wereTable 3
Behavior and observation result summaries for castrated horses treated with me
Measurement Time Period Me
Mann–Whitney Test Me
Behavioral score Day 0 3.
Day 1 2.
Day 2 2.
Day 3 2.
Visual Analog Score Day 0 18.
Day 1 10.
Day 2 8.
Day 3 9.
Stiffness Score Day 1 0.
Day 2 0.
Day 3 0.
Sheath Swelling Score Day 1 0.
Day 2 0.
Day 3 1.
t Test Me
Movement Index (ICE Tag) Period 1a 7,7
Period 2a 16,
Period 3a 18,
Stride length change (cm) Day 1 4.0
Day 2 2
Day 3 1
Sheath thickness (mm) Day 3 59.
Skin temperature (

C) Day 3 33.
Abbreviation: SE, standard error.
a Period 1 indicates 6:00 PM (day 0) to 7:00 AM (day 1); period 2 indicates 10:00
7:00 AM (day 3).very low. In spite of this, the movement score at the time of
leaving the chute was signiﬁcantly greater in control ani-
mals over meloxicam-treated animals at all observation
periods. On day 1 after castration, stride length was
signiﬁcantly longer in the meloxicam-treated horses (n ¼
25) than in controls (n ¼ 24) (meloxicam ¼ 179.6 cm vs.
control ¼ 156.7 cm, P < .006). There was no signiﬁcant
difference between groups or difference from day 0 mea-
surements at any other time period.
3.2.4. ICE TAG Accelerometers (Movement Evaluation)
During period 1 (6:00 PM [day 0]–7:00 AM [day 1]),
there was no difference between the control and
meloxicam-treated animals (treated ¼ 7,765 vs. control ¼
6,479, P ¼ .096), but for period 2 (10:00 AM [day 1]–7:00
AM [day 2]) and period 3 (10:00 AM [day 2]–7:00 AM [day
3]), the meloxicam-treated animals had signiﬁcantly
greater movement indices (treated ¼ 16,150 vs. control ¼
11,760, P ¼ .0052 and treated ¼ 18,900 vs. control ¼ 13,240,
P ¼ .0255), respectively.
3.2.5. Inﬂammation and Temperature Measurement (Day 3)
Meloxicam-treated animals had signiﬁcantly less sheath
swelling than control animals (treated¼ 59.56 mm, control
¼ 87.00 mm, P < .0001). There was no difference in skin
surface temperature between control and meloxicam-
treated animals.
3.2.6. Sheath Swelling Score
It was believed that a more accurate Sheath Swelling
Score was achieved when the animals were on the tilt table
(day 3). The Sheath Swelling Score at the time of the
treatments (day 1 and day 2) and while on the tilt tableloxicam and the control group.
loxicam Control P Value
dian Median
0 4.0 .0005
0 4.0 <.0001
0 3.0 .0048
0 3.0 .0051
0 28.5 .0023
0 25.5 <.0001
5 17.0 .0006
0 15.0 .0040
0 0.0 <.0001
0 0.0 <.0001
0 0.0 .017
0 1.0 <.0001
5 2.0 <.0001
0 2.0 .0008
an  SE Mean  SE
65  581 6,479  497 .096
150  928 11,760  753 .0052
900  1,573 13,240  1,632 .0255
2  4.53 3.47  4.36 .243
.58  5.76 2.84  3.99 .969
.40  4.35 3.99  3.14 .629
56  4.98 87.00  4.97 .0002
73  0.24 34.02  0.36 .5157
AM (day 1) to 7:00 AM (day 2); and period 3 indicates 10:00 AM (day 2) to
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treatment ¼ 0.0, control ¼ 1.0, P < .0001; day 2: treatment
¼ 0.5, control ¼ 2.0, P < .0001; day 3: treatment ¼ 1.0,
control¼ 2.0, P< .0008) overmeloxicam-treated animals at
all observation periods (day 1, day 2, and day 3).
4. Discussion
Meloxicam oral suspension was developed for cattle,
sheep, goats, and horses to control pain and inﬂammation
after castration and other surgical procedures. The product
is easy to deliver by direct oral dosing or can be top dressed
on feed. As meloxicam is tasteless, it can be administrated
in the feed, eliminating the need to restrain the horse
(unpublished results).
The pharmacokinetic and pharmacodynamics behavior
of commercial and noncommercial oral, IV, and intramus-
cular injection meloxicam products have been reported
[14,18–21]. The pharmacokinetic parameters of MOS are
similar to those reported for other oral meloxicam medi-
cation to horses. The EC50 for meloxicam using an estab-
lished carpus lameness model is reported to be 0.16 mg/mL
[18] and 0.20 mg/mL [19]. Meloxicam oral suspension at a
dosage of 0.6 mg/kg provided plasma concentrations that
exceeded the EC50 within 1 hour of administration and
were maintained for over 24 hours. In addition, the mean
residence time or time for 63.2% of administered melox-
icam dose to be eliminated was approximately 17 hours,
which makes daily dosing of meloxicam appropriate.
Multiple dosing of meloxicam for 5 days did not change
plasma peak and trough concentrations of meloxicam,
which supports long-term efﬁcacy and safety. This has been
observed with other meloxicam preparations [14,20,21].
There has been considerable research in pain mitigation
during castration in food animal species [22–24]. Larger
studies in horses have been lacking [10,12,13]. To our
knowledge, this is the ﬁrst clinical trial evaluating post-
operative pain management in a large number of horses for
up to 4 days after surgery. This study supports the ﬁndings
in other species that postoperative pain lasts for at least
several days after castration. Horses continued to show
signs of pain and surgical site swelling on day 3 after
castration, which would suggest that pain medication
should be continued at least until this time period.
It has been shown that behavioral parameters can be
valuable in assessment of pain, but there is limited infor-
mation for horses. The measurement of predeﬁned pos-
tures and movements has been shown to be useful in
comparing animals receiving analgesics and placebos
[25–27]. Pain scales and time budget of behavior have been
shown to be useful in evaluation of orthopedic pain using a
synovitis model [28]. In this study, behavioral analysis was
performed using a composite evaluation system modiﬁed
from the published literature [11,16,17]. It was important
that there was more than one evaluator, they were expe-
rienced in horse behavior, they were blinded to the treat-
ment groups, and they were validated as an appropriate
observer [17]. As the horses in this study were unhandled
animals, the Composite Pain Score used was developed to
be able to evaluate the horses from a distance and focused
on easily recognizable behaviors. The combination ofbehavioral scores is controversial but was conducted as
there is considerable variation in behavioral expressions
among horses. Horse grimace scales have also been shown
to effectively assess pain behaviors; however, facial ex-
pressions would have been difﬁcult to evaluate in this
study [29]. The behavioral scores and the visual analog
scores were highly signiﬁcantly different between the
meloxicam treated and placebo horses for all four obser-
vational periods, which would support the beneﬁts of
NSAID treatment in the ﬁrst few days after castration.
The Stiffness Score was obtained after the horses were
released from the restraining chute where they received
their treatments. As these were unbroken horses that have
had minimal handling, the Stiffness Score would be
considered to be less useful as they were easily excited and
could hidemovement alterations. This is conﬁrmed asmost
horses had a normal movement score. In spite of this, there
was a signiﬁcant difference in the mean scores between
groups. Stride length has been used as a measure of post-
operative pain in other species [22,23]. Some of the chal-
lenges in this study were the high variability of stride
length between horses, the number of horses who cantered
past the video camera, and the dynamic nature of move-
ment in horses, where both hind legs do not contact the
ground at the same time at the trot.
Leg accelerometers have been used extensively in
continually monitoring behaviors in dairy cattle [30,31].
Validation studies conducted before initiating the study
using the ICE Tag monitoring system showed that only the
Movement Index could be used with horses. The Movement
Index is generated based on the general walking movement
of the animal. This Index can be valuable in documenting
postcastration complications such as swelling, where ani-
mals have reduced movement [30,31]. Meloxicam-treated
animals had signiﬁcantly increased Movement Index
compared with placebo animals for observation periods 2
and 3which indicates that themeloxicam-treated horses are
more active within the paddock.
The prepuce sheath swelling was scored in the chute on
days 1 and 2, but on day 3, it was scored on the tilt table. It
was very clear that swelling could be best evaluated on the
tilt table where a thorough examination could be per-
formed. The severity of sheath swelling became more se-
vere from day 1 through day 3 for both treatment groups;
however, there was a very signiﬁcant reduction in swelling
in the meloxicam-treated animals compared with controls.
This difference was conﬁrmed with the caliper measure-
ments of the sheath thickness. The sheath thickness was
signiﬁcantly reduced in the meloxicam-treated animals
which demonstrates the anti-inﬂammatory effects of
meloxicam in horses. As some treated animals still had
swollen sheaths on day 3, it was believed that additional
daily meloxicam treatments would have been beneﬁcial in
these cases.
The intraincisional skin surface temperature was not
different between the treatment groups. This was not sur-
prising as variance among measurements was high and
subject to environmental inﬂuences.
As meloxicam is tasteless, it can be administrated in the
feed, eliminating the need to restrain the horse (unpub-
lished results).
M.E. Olson et al. / Journal of Equine Veterinary Science 35 (2015) 724–7307305. Conclusions
Daily administration of MOS at a dose of 0.6 mg/kg for
3 days signiﬁcantly reduces postsurgical pain and inﬂam-
mation in horses for at least 4 days after castration.
Meloxicam oral suspension may provide the veterinary
practitioner with a simple, safe, and effective method to
control pain and inﬂammation after castration in horses.
Provision of pain control and reduction of inﬂammation
should decrease the recovery period after castration. It is
expected that MOS could also be used for control of pain
and inﬂammation for other surgical procedures, but further
research needs to be conducted to demonstrate these
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